Prothena Corporation plc (NASDAQ: PRTA) Is Getting Increasingly Hard To Ignore

Currently, there are 53.68M common shares owned by the public and among those 46.42M shares have been available to trade.

The company’s stock has a 5-day price change of -4.64% and -22.12% over the past three months. PRTA shares are trading -46.23% year to date (YTD), with the 12-month market performance down to -71.45% lower. It has a 12-month low price of $19.52 and touched a high of $73.14 over the same period. PRTA has an average intraday trading volume of 515.29K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -7.25%, -9.38%, and -40.17% respectively.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Institutional ownership of Prothena Corporation plc (NASDAQ: PRTA) shares accounts for 98.56% of the company’s 53.68M shares outstanding.

It has a market capitalization of $1.05B and a beta (3y monthly) value of 0.20. The earnings-per-share (ttm) stands at -$3.25. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.20% over the week and 4.89% over the month.

Earnings per share for the fiscal year are expected to decrease by -70.21%, and 9.18% over the next financial year. EPS should grow at an annualized rate of 34.07% over the next five years, compared to 6.83% over the past 5-year period.

Looking at the support for the PRTA, a number of firms have released research notes about the stock. BofA Securities stated their Neutral rating for the stock in a research note on January 30, 2024, with the firm’s price target at $68-$38. Deutsche Bank coverage for the Prothena Corporation plc (PRTA) stock in a research note released on December 12, 2023 offered a Buy rating with a price target of $62. SVB Securities was of a view on April 24, 2023 that the stock is Outperform, while Piper Sandler gave the stock Overweight rating on January 27, 2023, issuing a price target of $94. RBC Capital Mkts on their part issued Sector Perform rating on November 04, 2022.

Most Popular

Related Posts